BRPI0514102A - compostos para inibição da enzima de proteassoma - Google Patents
compostos para inibição da enzima de proteassomaInfo
- Publication number
- BRPI0514102A BRPI0514102A BRPI0514102-8A BRPI0514102A BRPI0514102A BR PI0514102 A BRPI0514102 A BR PI0514102A BR PI0514102 A BRPI0514102 A BR PI0514102A BR PI0514102 A BRPI0514102 A BR PI0514102A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- peptide
- inhibition
- activities
- based compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title abstract 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000604 Hydrolases Proteins 0.000 abstract 1
- 102000004157 Hydrolases Human genes 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000037012 chymotrypsin-like activity Effects 0.000 abstract 1
- 150000002118 epoxides Chemical class 0.000 abstract 1
- 238000007306 functionalization reaction Methods 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 abstract 1
- 230000000269 nucleophilic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122020008634A BR122020008634B8 (pt) | 2004-08-06 | 2005-08-08 | compostos para inibição da enzima de proteassoma, composição farmacêutica compreendendo ditos compostos e usos terapêuticos dos mesmos |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59940104P | 2004-08-06 | 2004-08-06 | |
US60/599,401 | 2004-08-06 | ||
US61000104P | 2004-09-14 | 2004-09-14 | |
US60/610,001 | 2004-09-14 | ||
US11/106,879 US7232818B2 (en) | 2004-04-15 | 2005-04-14 | Compounds for enzyme inhibition |
US11/106,879 | 2005-04-14 | ||
PCT/US2005/028246 WO2006017842A1 (en) | 2004-08-06 | 2005-08-08 | Compounds for proteasome enzyme inhibition |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0514102A true BRPI0514102A (pt) | 2008-05-27 |
BRPI0514102B1 BRPI0514102B1 (pt) | 2020-07-07 |
BRPI0514102B8 BRPI0514102B8 (pt) | 2021-05-25 |
Family
ID=35502451
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0514102A BRPI0514102B8 (pt) | 2004-08-06 | 2005-08-08 | composto para inibição da enzima de proteassoma e composição farmacêutica compreendendo dito composto |
BR122020008634A BR122020008634B8 (pt) | 2004-08-06 | 2005-08-08 | compostos para inibição da enzima de proteassoma, composição farmacêutica compreendendo ditos compostos e usos terapêuticos dos mesmos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122020008634A BR122020008634B8 (pt) | 2004-08-06 | 2005-08-08 | compostos para inibição da enzima de proteassoma, composição farmacêutica compreendendo ditos compostos e usos terapêuticos dos mesmos |
Country Status (25)
Country | Link |
---|---|
US (12) | US7232818B2 (pt) |
EP (4) | EP1781688B1 (pt) |
JP (2) | JP4743720B2 (pt) |
KR (3) | KR101354280B1 (pt) |
CN (1) | CN102286070B (pt) |
AT (1) | ATE496062T1 (pt) |
AU (1) | AU2005271232B2 (pt) |
BR (2) | BRPI0514102B8 (pt) |
CA (1) | CA2589765C (pt) |
CY (3) | CY1116771T1 (pt) |
DE (1) | DE602005026019D1 (pt) |
DK (2) | DK3101026T3 (pt) |
ES (2) | ES2525248T3 (pt) |
FR (1) | FR16C0017I2 (pt) |
HK (4) | HK1103525A1 (pt) |
HU (2) | HUE038005T2 (pt) |
IL (3) | IL181127A (pt) |
LT (2) | LT3101026T (pt) |
LU (1) | LU93015I2 (pt) |
NO (2) | NO341015B1 (pt) |
PL (2) | PL3101026T3 (pt) |
PT (2) | PT3101026T (pt) |
SG (2) | SG155187A1 (pt) |
SI (2) | SI1781688T1 (pt) |
WO (1) | WO2006017842A1 (pt) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
EP1745064B1 (en) | 2004-04-15 | 2011-01-05 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
AU2005243140A1 (en) * | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
CA2565407A1 (en) * | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Compounds for enzyme inhibition |
DK1830838T3 (da) | 2004-12-03 | 2013-01-21 | Dana Farber Cancer Inst Inc | Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme |
PL2261236T3 (pl) * | 2004-12-07 | 2015-12-31 | Onyx Therapeutics Inc | Kompozycja do hamowania proteasomu |
PT2623113T (pt) | 2005-11-09 | 2017-07-14 | Onyx Therapeutics Inc | Compostos para inibição de enzimas |
SI2041158T1 (sl) * | 2006-06-19 | 2013-09-30 | Onyx Therapeutics, Inc. | Peptidni epoksiketoni za inhibicijo proteasomov |
EP2040694A2 (en) * | 2006-07-14 | 2009-04-01 | VIB vzw | Use of ppar-alpha agonists to treat skeletal muscle wasting disorders |
US7642369B2 (en) * | 2006-09-12 | 2010-01-05 | University Of Kentucky Research Foundation | Epoxyketone-based immunoproteasome inhibitors |
AU2016231532B2 (en) * | 2007-10-04 | 2018-05-10 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
AU2013203566B2 (en) * | 2007-10-04 | 2016-10-13 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
TWI501773B (zh) | 2007-10-04 | 2015-10-01 | Onyx Therapeutics Inc | 結晶肽環氧酮蛋白酶抑制劑以及胺基酸酮環氧化物之合成 |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
EP2088205A1 (en) | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: A diagnosis marker and therapeutic target of chronic rejection. |
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
JP2011519975A (ja) * | 2008-05-12 | 2011-07-14 | ネレアス ファーマシューティカルズ インコーポレイテッド | プロテアソーム阻害剤としてのサリノスポラミド誘導体 |
BRPI0919668A2 (pt) | 2008-10-21 | 2018-05-29 | Onyx Therapeutics, Inc. | terapia de combinação com epóxi-cetonas de peptídeo |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
US20110009332A1 (en) * | 2009-07-09 | 2011-01-13 | Southwest Research Institute | Therapeutic Treatment Of Wounds |
GB0914883D0 (en) | 2009-08-26 | 2009-09-30 | Univ Belfast | Compound |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
MX2012010017A (es) | 2010-03-01 | 2012-10-01 | Onyx Therapeutics Inc | Compuestos de para la inhibicion de inmunoproteasomas. |
MX2012011604A (es) | 2010-04-07 | 2013-02-27 | Onyx Therapeutics Inc | Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino. |
US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
WO2012135528A2 (en) | 2011-03-29 | 2012-10-04 | Texas Tech University System | Galectin-3c combination therapy for human cancer |
WO2013009923A1 (en) * | 2011-07-13 | 2013-01-17 | Creighton University | Methods of promoting neuron growth |
JP6286358B2 (ja) | 2011-11-11 | 2018-02-28 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | プロテアソーム阻害剤に応答するバイオマーカー |
CA2855356A1 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
WO2013112601A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
DK2814849T3 (da) | 2012-02-15 | 2020-03-09 | Cydex Pharmaceuticals Inc | Fremgangsmåde til fremstilling af cyclodextrin-derivater |
CA2873044C (en) * | 2012-05-08 | 2021-01-26 | Onyx Therapeutics, Inc. | Cylodextrin complexation methods for formulating peptide proteasome inhibitors |
WO2014011695A2 (en) | 2012-07-09 | 2014-01-16 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
AU2013292647B2 (en) | 2012-07-18 | 2018-03-15 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
WO2014029022A1 (en) * | 2012-08-21 | 2014-02-27 | Abdelmalik Slassi | Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors |
MX360192B (es) | 2012-10-22 | 2018-10-24 | Cydex Pharmaceuticals Inc | Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas. |
SG10201707464SA (en) | 2013-03-13 | 2017-10-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
AU2014240122B2 (en) | 2013-03-14 | 2019-02-14 | Onyx Therapeutics, Inc. | Dipeptide and tripeptide epoxy ketone protease inhibitors |
AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
US20160166632A1 (en) | 2013-07-19 | 2016-06-16 | Onyx Therapeutics, Inc. | Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers |
CN103360348B (zh) * | 2013-07-25 | 2015-06-24 | 苏州鹏旭医药科技有限公司 | 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法 |
CA2920220A1 (en) * | 2013-09-06 | 2015-03-12 | Sandoz Ag | Synthesis of peptide epoxy ketones |
EP3041832A1 (en) * | 2013-09-06 | 2016-07-13 | Sandoz AG | Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib |
WO2015121769A1 (en) | 2014-02-13 | 2015-08-20 | Ranbaxy Laboratories Limited | Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate |
CN103864889B (zh) * | 2014-04-04 | 2017-01-11 | 重庆泰濠制药有限公司 | 环氧酮化合物、其制备方法及卡非佐米的制备方法 |
US10851184B2 (en) | 2014-08-22 | 2020-12-01 | Cydex Pharmaceuticals, Inc. | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
US10329325B2 (en) | 2014-09-24 | 2019-06-25 | Biophore India Pharmaceuticals Pvt. Ltd | Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide |
WO2016069479A1 (en) | 2014-10-27 | 2016-05-06 | Apicore Us Llc | Methods of making carfilzomib and intermediates thereof |
CN104402973A (zh) * | 2014-11-24 | 2015-03-11 | 重庆泰濠制药有限公司 | 一种卡非佐米无定型晶的制备方法 |
US10253066B2 (en) | 2014-12-02 | 2019-04-09 | Fresenius Kabi Oncology Limited | Process for purification of Carfilzomib |
WO2016108204A1 (en) | 2014-12-31 | 2016-07-07 | Dr. Reddy's Laboratories Limited | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib |
WO2016170544A1 (en) * | 2015-04-22 | 2016-10-27 | Msn Laboratories Private Limited | Process for the preparation of (2s)-n-((s)-1-((s)-4-methyl-1-((r)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((s)-2-(2-morpholino acetamido)-4-phenylbutanamido)-4-methylpentanamide |
WO2016185450A1 (en) | 2015-05-21 | 2016-11-24 | Laurus Labs Private Limited | An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof |
CN106317188A (zh) * | 2015-06-18 | 2017-01-11 | 重庆医药工业研究院有限责任公司 | 一种制备卡非佐米无定型物的方法 |
WO2017032487A1 (en) | 2015-08-27 | 2017-03-02 | Technische Universität München | Proteasome inhibitor comprising a signal-emitting moiety |
US20180362580A1 (en) | 2015-12-11 | 2018-12-20 | Mylan Laboratories Limited | Crystalline and amorphous forms of carfilzomib |
TWI636052B (zh) * | 2015-12-31 | 2018-09-21 | 中化合成生技股份有限公司 | 無定形卡非佐米(i)的製備方法 |
US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
TWI759301B (zh) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
EP3494126A1 (en) | 2016-08-02 | 2019-06-12 | Synthon BV | Process for making carfilzomib |
ES2842575T3 (es) | 2016-08-05 | 2021-07-14 | Amgen Inc | Síntesis de (S)-2-amino-4-metil-1-((R)-2-metiloxiran-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma |
CN109689635A (zh) | 2016-09-14 | 2019-04-26 | 费森尤斯卡比肿瘤学有限公司 | 一种用于纯化卡非佐米中间体的方法 |
US11597708B2 (en) | 2016-09-16 | 2023-03-07 | Hsf Pharmaceuticals Sa | Inhibitors of heat shock factors and uses thereof |
EP3330260A1 (en) | 2016-12-01 | 2018-06-06 | Enantia, S.L. | Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib |
WO2019053611A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | POLY THERAPY FOR THE TREATMENT OF CANCER |
WO2019099715A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Stable compositions of pegylated carfilzomib compounds |
CN117051096A (zh) * | 2017-12-08 | 2023-11-14 | 神经Gx有限责任公司 | 用于阿尔茨海默病的同步化细胞周期基因表达测试及相关治疗方法 |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
US10689416B2 (en) * | 2017-12-30 | 2020-06-23 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
CA3043103C (en) * | 2017-12-30 | 2021-02-09 | Unity Biotechnology | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
SG11202012765PA (en) * | 2018-06-22 | 2021-01-28 | Ucl Business Ltd | Novel compounds |
WO2021072212A1 (en) * | 2019-10-11 | 2021-04-15 | Mayo Foundation For Medical Education And Research | Proteasome inhibitors |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2024069240A2 (en) | 2022-09-29 | 2024-04-04 | Takeda Pharmaceutical Company Limited | Cd38-binding fusion protein combination therapy |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US569748A (en) | 1896-10-20 | Henry edmunds | ||
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4990448A (en) | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
US5071957A (en) | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
US6099851A (en) * | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
US6831099B1 (en) * | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
JP2003528039A (ja) | 1999-10-20 | 2003-09-24 | オステオスクリーン,インコーポレイテッド | 骨および毛成長を刺激するためのプロテアソーム活性のインヒビター |
WO2003059898A2 (en) | 2002-01-08 | 2003-07-24 | Eisai Co. Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
EP1745064B1 (en) * | 2004-04-15 | 2011-01-05 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
AU2005243140A1 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
CA2565407A1 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Compounds for enzyme inhibition |
-
2005
- 2005-04-14 US US11/106,879 patent/US7232818B2/en active Active
- 2005-08-08 WO PCT/US2005/028246 patent/WO2006017842A1/en active Application Filing
- 2005-08-08 CN CN201110145272.7A patent/CN102286070B/zh active Active
- 2005-08-08 KR KR1020077003533A patent/KR101354280B1/ko active Protection Beyond IP Right Term
- 2005-08-08 US US11/199,899 patent/US7417042B2/en active Active
- 2005-08-08 SG SG200905204-4A patent/SG155187A1/en unknown
- 2005-08-08 KR KR1020137016063A patent/KR20130080064A/ko not_active Application Discontinuation
- 2005-08-08 PT PT161664925T patent/PT3101026T/pt unknown
- 2005-08-08 DE DE602005026019T patent/DE602005026019D1/de active Active
- 2005-08-08 LT LTEP16166492.5T patent/LT3101026T/lt unknown
- 2005-08-08 AU AU2005271232A patent/AU2005271232B2/en active Active
- 2005-08-08 KR KR1020127030701A patent/KR101544258B1/ko active Protection Beyond IP Right Term
- 2005-08-08 BR BRPI0514102A patent/BRPI0514102B8/pt active IP Right Grant
- 2005-08-08 CA CA2589765A patent/CA2589765C/en active Active
- 2005-08-08 HU HUE16166492A patent/HUE038005T2/hu unknown
- 2005-08-08 DK DK16166492.5T patent/DK3101026T3/en active
- 2005-08-08 SG SG10201701794UA patent/SG10201701794UA/en unknown
- 2005-08-08 BR BR122020008634A patent/BR122020008634B8/pt active IP Right Grant
- 2005-08-08 PL PL16166492T patent/PL3101026T3/pl unknown
- 2005-08-08 SI SI200531264T patent/SI1781688T1/sl unknown
- 2005-08-08 JP JP2007525077A patent/JP4743720B2/ja active Active
- 2005-08-08 ES ES10012498.1T patent/ES2525248T3/es active Active
- 2005-08-08 EP EP05784484A patent/EP1781688B1/en active Active
- 2005-08-08 EP EP10012497.3A patent/EP2270026B1/en active Active
- 2005-08-08 EP EP10012498.1A patent/EP2266999B1/en active Active
- 2005-08-08 AT AT05784484T patent/ATE496062T1/de active
- 2005-08-08 PT PT05784484T patent/PT1781688E/pt unknown
- 2005-08-08 EP EP16166492.5A patent/EP3101026B1/en active Active
- 2005-08-08 ES ES16166492.5T patent/ES2674277T3/es active Active
- 2005-08-08 SI SI200532211T patent/SI3101026T1/en unknown
- 2005-08-08 DK DK05784484.7T patent/DK1781688T3/da active
- 2005-08-08 PL PL05784484T patent/PL1781688T3/pl unknown
-
2007
- 2007-02-01 IL IL181127A patent/IL181127A/en active Protection Beyond IP Right Term
- 2007-02-20 NO NO20070965A patent/NO341015B1/no unknown
- 2007-04-11 US US11/786,217 patent/US7491704B2/en active Active
- 2007-11-07 HK HK07112064.9A patent/HK1103525A1/xx unknown
-
2011
- 2011-03-04 JP JP2011047047A patent/JP5394423B2/ja active Active
- 2011-04-04 CY CY20111100347T patent/CY1116771T1/el unknown
- 2011-06-29 HK HK11106710A patent/HK1152536A1/xx unknown
- 2011-07-04 HK HK11106767.5A patent/HK1152716A1/zh unknown
-
2012
- 2012-08-22 IL IL221572A patent/IL221572B/en active IP Right Grant
-
2014
- 2014-08-06 US US14/452,844 patent/US20140342977A1/en not_active Abandoned
-
2015
- 2015-08-26 US US14/835,876 patent/US20150361134A1/en not_active Abandoned
-
2016
- 2016-04-05 HU HUS1600014C patent/HUS1600014I1/hu unknown
- 2016-04-06 LU LU93015C patent/LU93015I2/xx unknown
- 2016-04-08 US US15/094,088 patent/US20160222057A1/en not_active Abandoned
- 2016-04-12 LT LTPA2016010C patent/LTC1781688I2/lt unknown
- 2016-04-22 CY CY2016009C patent/CY2016009I2/el unknown
- 2016-05-12 FR FR16C0017C patent/FR16C0017I2/fr active Active
-
2017
- 2017-03-14 NO NO20170381A patent/NO344397B1/no unknown
- 2017-05-18 HK HK17105016.0A patent/HK1231491A1/zh unknown
-
2018
- 2018-02-13 US US15/895,120 patent/US20180170962A1/en not_active Abandoned
- 2018-06-20 CY CY181100642T patent/CY1120677T1/el unknown
- 2018-09-20 IL IL261892A patent/IL261892B/en active IP Right Grant
-
2019
- 2019-03-13 US US16/351,669 patent/US20190211058A1/en not_active Abandoned
- 2019-10-31 US US16/669,601 patent/US20200071356A1/en not_active Abandoned
-
2020
- 2020-06-26 US US16/912,806 patent/US20200325172A1/en not_active Abandoned
-
2021
- 2021-02-08 US US17/169,990 patent/US20210179663A1/en not_active Abandoned
-
2022
- 2022-04-29 US US17/733,077 patent/US20220267372A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0514102A (pt) | compostos para inibição da enzima de proteassoma | |
BRPI0510802A (pt) | compostos para inibição de enzima | |
BRPI0618468A2 (pt) | compostos para inibição de enzima | |
BRPI0509879A (pt) | compostos para inibição enzimática | |
CR9962A (es) | Compuestos para inhibicion enzimatica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/07/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B25A | Requested transfer of rights approved |
Owner name: ONYX THERAPEUTICS, INC. (US) |
|
B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI NO 52402.003341/2021-41 ORIGEM: 25O VF DO RIO DE JANEIRO PROCESSO NO: 5087568-96.2020.4.02.5101 NULIDADE DA PATENTE DE INVENCAO COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: NATCOFARMA DO BRASIL LTDA REU(S): ONYX THERAPEUTICS, INC E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI |
|
B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI NO 52402.004484/2021-70 ORIGEM: 13O VF DO RIO DE JANEIRO PROCESSO NO: 5030973-43.2021.4.02.5101 NULIDADE DE ATO ADMINISTRATIVO AUTOR: LIBBS FARMACEUTICA LTDA. REU(S): ONYX THERAPEUTICS, INC. E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |